Danaher Corp. (DHR) Signaled Signs of a Stable Bioprocessing Segment

Core Viewpoint - The Meridian Hedged Equity Fund's fourth-quarter 2025 performance was influenced by optimism regarding monetary easing and concerns about economic growth and valuations, with a modest gain of 0.08% compared to the S&P 500 Index's 2.66% return and the CBOE S&P 500 BuyWrite Index's 6.53% return [1] Group 1: Fund Performance - In Q4 2025, the Fund gained 0.08%, while the S&P 500 Index returned 2.66% and the CBOE S&P 500 BuyWrite Index returned 6.53% [1] - The Fund's performance contributed positively to robust annual results despite a cooling market sentiment later in the quarter [1] Group 2: Danaher Corporation (NYSE:DHR) - Danaher Corporation was highlighted as a key contributor to the portfolio performance, with a market capitalization of $150.16 billion [2][4] - The stock closed at $212.58 per share on February 13, 2026, with a one-month return of -9.92% and a twelve-month return of 3.04% [2] - Danaher is recognized for its strong presence in life sciences and diagnostics, particularly in bioprocessing, medical research, and clinical diagnostics [3] Group 3: Investment Insights - The Fund holds Danaher for its competitive positioning in growing end-markets and consistent free cash flow generation, with management reaffirming forward guidance [3] - In 2025, Danaher reported sales of $24.6 billion and core revenue growth of 2% [4] - Despite recognizing Danaher's potential, the Fund suggests that certain AI stocks may offer greater upside potential and less downside risk [4]